Gene Expression Analysis of Circulating Hormone Refractory Prostate Cancer Micrometastases

reportActive / Technical Report | Accession Number: ADA506021 | Open PDF

Abstract:

This annual report for the Physician Research Training Award focuses on progress in the genetic analysis of circulating hormone refractory prostate cancer micrometastases. As metastatic tissue is often inaccessible in advanced prostate cancer patients, analysis of circulating tumor cells may provide understanding of the biology of hormone refractory prostate cancer as well as chemotherapy resistance. Oligonucleotide array comparative genomic hybridization allows the assessment of genetic changes that may occur in the process of metastasis and chemotherapy resistance. Genomic profiling using this technology goes beyond cell counting, and circumvents technical complexities related to working with RNA. Reproducible genomic alterations are observed A functional collagen adhesion matrix CAM assay was used to enrich CTCs from prostate cancer patients blood. CAM ingestion and epithelial immuno-staining identified CTCs, which were genotyped using oligonucleotide array comparative genomic hybridization. The highest CTC counts were observed in men with metastatic hormone refractory prostate cancer compared to castration sensitive prostate cancer. Copy number profiles for CRPC CTCs were similar to paired solid tumor DNA, and distinct from corresponding DNA from the residual CAM-depleted blood. CAM CTC enrichment may allow cellular and genetic analyses in prostate cancer.

Author(s):
Rosenberg, Jonathan
Author Organization(s):
CALIFORNIA UNIV SAN FRANCISCO
Descriptive Note:
Annual rept. 1 Jan-31 Dec 2008
Supplementary Note:
The original document contains color images.
Pagination:
0032

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Contract/Grant Number(s):
W81XWH-05-1-0175
Monitor Series:
USAMRMC
 Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.3_Planning; JCA_1.2.3_Educating; JCA_5.5.2_Task; JCA_5.5_Direct; JCA_1.2.1_Training; JCA_7.2.1_Mitigate Lethal Effects; JCA_7.2_Mitigate; JCA_7_Protection; JCA_1.2.5_Lessons Learned; JCA_1.2.7_Experimentation
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*PROSTATE CANCER, *METASTASIS, *INGESTION(PHYSIOLOGY), *CHEMOTHERAPY, *BLOOD CIRCULATION, *HORMONES, GENES, RESPONSE(BIOLOGY), ERYTHROCYTES, CELLS(BIOLOGY), OLIGOMERS, EXCISION, RESISTANCE(BIOLOGY), COLLAGEN, NUCLEOTIDES, DEOXYRIBONUCLEIC ACIDS, NEOPLASMS, ARRAYS, COUNTING METHODS, ADHESION, GENOME, TISSUES(BIOLOGY)
Field(s)/Group(s):
Medicine and Medical Research, Microbiology
Keyword(s):
CIRCULATING TUMOR CELLS, PROSTATE CANCER, CHEMOTHERAPY RESISTANCE, GENOMIC ANALYSIS
Report Date:
2009 Jan 01
Creation Date:
2009 Oct 07